US agencies are moving fast on psychedelic therapies: clinical guidance, regulatory readiness, cross-agency work, following April's EO on mental health and ARPA-H's $100M moonshot. Europe shouldn't wait. PAREA wants mental health reflected across the EU Biotech Act. tinyurl.com/parea-news

🚨 The June EU Insights newsletter is out 🚨 Highlights: • PAREA's Biotech Act recommendations to the European Commission. • Updates from the European Academy of Neurology Congress. • PsyPal trial expansion across Europe. • Francisca Silva speaking at PSY-NET during FENS. Read more: lnkd.in/dc3RXaAd

We're pleased to welcome Psychedelic Lived Experiences as PAREA's newest Community Supporter! They elevate patient voices in psychedelic care through advocacy, education, and community because lived experience is genuine expertise. Learn more: parea.eu/parea-news/p...

We submitted our response to the European Commission’s consultation on the EU4Health 2027 Work Programme. We call for stronger health systems to address NCDs, with mental health as a core priority, alongside support for workforce development, implementation, and access to care. lnkd.in/dSQJauZh

PAREA has submitted recommendations to the EU Commission’s upcoming Biotech Act consultation, calling for mental health innovation to be included in Europe’s biotech strategy. Mental health innovation is both a public health priority and a competitiveness opportunity for Europe. lnkd.in/ee6cEgb8

France expands access to ketamine for patients in suicidal crisis. A 3 year programme allows IV racemic ketamine for adults with acute suicidal ideation, prescribed by psychiatrists and delivered in hospitals. Based on strong evidence and lower cost compared to esketamine. parea.eu/parea-news/f...

At the EPA Congress in Prague, PAREA engaged with clinicians and professionals on the role of psychedelic therapies in mental health care. Strong turnout for David Nutt’s sessions reflects growing interest in moving these approaches into clinical practice. More here: tinyurl.com/parea-at-the...

Today marks the launch of a new PsyPal guidance paper on how to standardise and implement psychedelic therapies in Europe. PAREA contributed to this work alongside partners in the PsyPal consortium. It outlines practical steps for moving toward real-world integration. tinyurl.com/psypal-guida...

PAREA is co-organising a webinar on the EU-funded PsyPal project, exploring psilocybin-assisted therapy for psychological distress in palliative care, incl. neurological conditions. 13 April, 14:00 to 15:30 CEST, with the EU Health Policy Platform. Register here: tinyurl.com/psypal-webinar

PAREA will be at the European Psychiatric Association Congress in Prague, 28–31 March. We will be hosting a stand to engage with the psychiatric community on the current status and potential of psychedelic therapies. Find us at our stand in the exhibition hall! More info: parea.eu/events/parea...

A psychedelic compound, bretisilocin, has entered the EMA PRIME scheme for major depressive disorder. PRIME supports high need medicines through early regulatory engagement, marking a meaningful step for Europe’s role in mental health innovation. Read more: tinyurl.com/news-release...

Webinar on legal pathways for psychedelic therapies in Europe, March 20 at 18:00 CET. PAREA joins UPRA and Ukraine’s Public Health Centre, with Marion Haberkamp, João Taborda da Gama, and Pavel Pachta. Register here: parea.eu/events/webin...

Join our European Parliament event on psychedelic research and access for war related mental health needs in Ukraine, including PTSD among veterans. 6 May 2026, 14:30 to 16:30, Brussels and online Register here: parea.eu/events/psych...

We welcome HYSTELICA as PAREA’s newest Community Supporter! The nonprofit advances psychedelic science for women through research, advocacy, and education. They focus on how psychedelics interact with female biology and closing gaps in women’s health research. More here: tinyurl.com/hystelica

Compass Pathways released topline data from its second Phase 3 trial of COMP360 psilocybin in treatment resistant depression. In COMP006 (n=581), two 25 mg doses showed a -3.8 MADRS difference vs 1 mg at Week 6. Prior Phase 3 data showed -3.6 vs placebo. More: tinyurl.com/readout-for-...

Spain’s Parliament hosted its first conference on psychedelic assisted psychotherapies on February 13. Clinicians, researchers, and regulators focused on evidence, responsible training, and equity in access. The debate has now formally entered the legislative arena. Learn more: tinyurl.com/spain-pap

PAREA submitted feedback on the European Commission’s ERA Act consultation, urging mental health as a strategic R&I priority and better coordinated funding that protects scientific freedom and speeds translation into practice. Learn more: parea.eu/parea-news/p...

EU institutions have agreed on the 1st major revision of pharmaceutical legislation in 20 years, reshaping incentives, access rules, and introducing regulatory sandboxes. PAREA will keep pushing for mental health to be recognised as the package moves forward. Learn more: tinyurl.com/pharma-legis...

New article maps key regulatory and clinical hurdles for bringing psychedelic therapies into EU healthcare. It underlines HTA as the decisive barrier and notes psychotherapy + pharmacotherapy as the gold standard, raising questions for assessing added value. More details: tinyurl.com/therapy-path...

What Europe’s health systems will require to implement psychedelic therapies — PAREA

A new article published in European Neuropsychopharmacology provides a critical assessment of what psychedelic therapi es would need in order to be integrated into European healthcare systems. ...

tinyurl.com

PAREA will join the PSYCH Symposium in London on Dec 4. Our Project Officer, Francisca Silva, will speak on integrating psychedelic medicines into healthcare alongside the MIND Foundation, Dr Liliana Galindo and Jeff Smith MP. Learn more about the conference here: www.psychsymposium.com/agenda

The US just launched EVIDENT, a 100M mental health moonshot days after PAREA called for a mission driven mental health moonshot in Europe. Neuroplastogens included. Clear signal that mental health innovation is going strategic. Europe has a window to lead. Learn more: parea.eu/parea-news/1...

Mental health innovation is rising in Europe and PAREA is at the centre. From calling for a European Mental Health Moonshot to EU-backed psychedelic trials, new members, major policy input, and the PsyPal trial now recruiting. Read the full newsletter: view.flodesk.com/emails/691d8...

PAREA welcomes the Women’s Brain Foundation as a new full member. Together, we’re pushing for sex and gender differences to be systematically recognised in mental health and psychedelic research, policy, and innovation across Europe. Learn more: view.flodesk.com/emails/6911d...

PAREA is partnering with the HoloMind: Psychedelic Therapy and Integration Conference 2025, Nov 15–16 in Warsaw and online. Experts will explore how psychedelics can help treat depression, PTSD, and addiction, and how Europe can connect evidence, ethics, and practice. holomind.org/en/2nd-editi...

We’re proud to support the first-ever Psychedelic Lived Experiences Summit! Nov 21-23| Free & Virtual This event bridges science and lived experience to explore psychedelic healing with 50+ speakers including patients, clinicians & researchers. 🎟️ Register: psychedeliclivedexperiences.com/summit

Our Project Officer Francisca Silva will represent PAREA at IMBAS 2025 – Ireland’s leading psychedelic research conference, Oct 31–Nov 1 at Trinity College Dublin. She'll share a EU perspective on the landscape of psychedelic therapies’ development and integration in healthcare. www.idpat.ie/events

The ALPS Awareness Lectures on Psychedelic Science return to Geneva on 24–25 October at Campus Biotech. Hosted by the ALPS Foundation, PAREA’s community supporter, the event showcases the latest expertise in psychedelic science and therapy. Learn more: www.alpsconference.com

To mark #WorldMentalHealthDay, PAREA contributed feedback to the EU’s next long-term budget. Our message: make mental health central to Europe’s innovation agenda. We call for decisive action to ensure the next generation of mental health treatments are accessible to all who need them.

Mental health conditions cause more years of ill-health than cancer, diabetes & heart disease combined, yet innovation has stalled. Join us 4 November in Brussels & online for our hybrid event, exploring how Europe can go from lagging to leading in mental health innovation. parea.eu/events/nov4

The EMA’s updated guideline on depression treatment takes effect today, with a dedicated section on psychedelics. PAREA contributed >10 comments during consultation, many of which shaped the final text. See the revised guideline here: tinyurl.com/ema-gl